Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. research hub

FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.

This study is testing if adding a new drug, ivosidenib, to an existing one, oral azacitidine, can help people over 55 with a specific type of leukaemia (AML with IDH1 mutation) stay well after treatment. It focuses on preventing the cancer from returning.